Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has a beta value of 2.17 and has seen 2,400,880 shares traded in the recent trading session. The company, currently valued at $79.2 Million, closed the recent trade at $2.35 per share which meant it gained $0.54 on the day or 29.83% during that session. The IDRA stock price is -52.34% off its 52-week high price of $3.58 and 65.53% above the 52-week low of $0.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 135.45 Million shares traded. The 3-month trading volume is 186.85 Million shares.
The consensus among analysts is that Idera Pharmaceuticals, Inc. (IDRA) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 6 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.39.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) trade information
Sporting 32.04% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 02 when the IDRA stock price touched $2.47 or saw a rise of 2.83%. Year-to-date, Idera Pharmaceuticals, Inc. shares have moved 31.87%, while the 5-day performance has seen it change 31.87%. Over the past 30 days, the shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) have changed 31.15%. Short interest in the company has seen 410.7 Million shares shorted with days to cover at 2.2.
Wall Street analysts have a consensus price target for the stock at $7.6, which means that the shares’ value could jump 223.4% from current levels. The projected low price target is $5 while the price target rests at a high of $10. In that case, then, we find that the current price level is +325.53% off the targeted high while a plunge would see the stock lose 112.77% from current levels.
Idera Pharmaceuticals, Inc. (IDRA) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +4.8% over the past 5 years. Earnings growth for 2020 is a modest +-31.6% while over the next 5 years, the company’s earnings are expected to increase by 0%.